Stock Scorecard
Stock Summary for Acorda Therapeutics Inc (ACOR) - $0.66 as of 4/11/2024 4:31:38 PM EST
Total Score
12 out of 29
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for ACOR
Positive earnings growth | |
P/E ratio less than Industry P/E Ratio | |
P/E ratio less than Sector P/E Ratio | |
P/E ratio that is half the growth rate (or less) | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Positive net income past year and 12 trailing months | |
Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for ACOR
Revenue growing by at least 20% average per year over the last 5 years | |
Market Capitalization under 2 billion | |
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for ACOR
Declared an ex-dividend date | |
Forward annual dividend rate greater than 2 | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Current ratio most recent quarter greater than 2 |
Bonus Criteria for ACOR
P/E ratio less than five-year Average P/E ratio | |
Last Price to 52 Week Low Ratio Less Than 1 | |
Total Cash Per Share > Last Day Price | |
P/S Ratio < 1 | |
P/B Ratio < 1 |
Financial Details for ACOR
Company Overview |
|
---|---|
Ticker | ACOR |
Company Name | Acorda Therapeutics Inc |
Country | USA |
Description | Acorda Therapeutics, Inc., a biopharmaceutical company, develops and markets therapies for neurological disorders in the United States. The company is headquartered in Ardsley, New York. |
Sector Name | LIFE SCIENCES |
Industry Name | BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) |
Most Recent Quarter | 3/31/2024 |
Next Earnings Date | 5/2/2024 |
Stock Price History |
|
Last Day Price | 0.66 |
Last Day Price Updated | 4/11/2024 4:31:38 PM EST |
Last Day Volume | N/A |
Average Daily Volume | 261,493 |
52-Week High | 24.20 |
52-Week Low | 0.61 |
Last Price to 52 Week Low | 8.20% |
Valuation Measures |
|
Trailing PE | 0.34 |
Industry PE | 58.56 |
Sector PE | 60.54 |
5-Year Average PE | -3.82 |
Free Cash Flow Ratio | 0.03 |
Industry Free Cash Flow Ratio | 18.64 |
Sector Free Cash Flow Ratio | 30.19 |
Current Ratio Most Recent Quarter | 0.33 |
Total Cash Per Share | 24.14 |
Book Value Per Share Most Recent Quarter | 47.47 |
Price to Book Ratio | 0.05 |
Industry Price to Book Ratio | 7.50 |
Sector Price to Book Ratio | 22.08 |
Price to Sales Ratio Twelve Trailing Months | 0.01 |
Industry Price to Sales Ratio Twelve Trailing Months | 9.49 |
Sector Price to Sales Ratio Twelve Trailing Months | 5.16 |
Share Statistics |
|
Total Shares Outstanding | 1,242,100 |
Market Capitalization | 819,786 |
Institutional Ownership | N/A |
Dividends |
|
Ex-Dividend Date | N/A |
Last Dividend Amount | 0.00 |
Current Dividend Amount | 0.00 |
Dividend Aristocrat? | False |
Trailing Annual Dividend Rate | 0.00 |
Trailing Annual Dividend Yield | 1.86% |
Forward Annual Dividend Rate | 0.00 |
Forward Annual Dividend Yield | 0.00% |
5-Year Dividend Payments Count | 0 |
3-Year Average Dividend Yield | 0.00% |
5-Year Average Dividend Yield | 0.00% |
1-Year Dividend Growth Rate Percentage | 0.00% |
3-Year Dividend Growth Rate Percentage | 0.00% |
5-Year Dividend Growth Rate Percentage | 0.00% |
All-Time Dividend Growth Rate Percentage | 0.00% |
Dividend Payout Ratio | N/A |
Income Statement |
|
Quarterly Earnings Growth YOY | 587.00% |
Annual Earnings Growth | -283.60% |
Reported EPS 12 Trailing Months | 2.61 |
Reported EPS Past Year | -225.81 |
Reported EPS Prior Year | -43.31 |
Net Income Twelve Trailing Months | -252,854,000 |
Net Income Past Year | -252,854,000 |
Net Income Prior Year | -65,916,000 |
Quarterly Revenue Growth YOY | -17.30% |
5-Year Revenue Growth | -28.18% |
Balance Sheet |
|
Total Cash Most Recent Quarter | 29,979,000 |
Total Cash Past Year | 29,979,000 |
Total Cash Prior Year | 37,536,000 |
Net Cash Position Most Recent Quarter | -156,164,000 |
Net Cash Position Past Year | -156,164,000 |
Long Term Debt Past Year | 186,143,000 |
Long Term Debt Prior Year | 167,031,000 |
Total Debt Most Recent Quarter | 186,143,000 |
Equity to Debt Ratio Past Year | -5.60 |
Equity to Debt Ratio Most Recent Quarter | -5.60 |
Total Stockholder Equity Past Year | -157,956,000 |
Total Stockholder Equity Prior Year | 93,622,000 |
Total Stockholder Equity Most Recent Quarter | -157,956,000 |
Options |
|
Put/Call Ratio | 0.00 |
Has Options | False |
Liquidity Rating | |
Technical Analysis |
|
Yahoo Finance Chart | Yahoo Finance Chart |
MACD | -3.46 |
MACD Signal | -2.56 |
20-Day Bollinger Lower Band | 4.32 |
20-Day Bollinger Middle Band | 12.86 |
20-Day Bollinger Upper Band | 21.40 |
Beta | 1.42 |
RSI | 16.53 |
50-Day SMA | 12.95 |
200-Day SMA | 45.37 |
System |
|
Modified | 4/12/2024 4:32:27 PM EST |